Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the... see more

Recent & Breaking News (OTCPK:HALB)

Halberd Corporation Now an Official US Government Contractor

Newsfile January 5, 2022

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

Newsfile December 20, 2021

Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

Newsfile December 15, 2021

Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

Accesswire December 13, 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

Newsfile December 13, 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE

Accesswire December 6, 2021

Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer's Disease

Accesswire November 22, 2021

Halberd Successfully Eradicates TNF-alpha, Major Contributing Factor to Alzheimer's Disease

Newsfile November 22, 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

Newsfile November 8, 2021

GTX Corp Begins Selling Vita-Shield-Max Immune Support Nutraceutical

GlobeNewswire November 2, 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer's Disease

Newsfile November 1, 2021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

Newsfile October 25, 2021

Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure

Newsfile October 20, 2021

Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement

Newsfile October 12, 2021

Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement

Accesswire October 12, 2021

Halberd Corporation CEO Letter

Newsfile October 7, 2021

Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon

Accesswire October 5, 2021

Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement

Newsfile September 22, 2021

Halberd's Treatment Eradicates Primary Building Block of Alzheimer's Disease

Accesswire September 13, 2021

Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions

Accesswire September 8, 2021